Heparin and low molecular weight heparin prolong prothrombin times in patients on warfarin treatment

Clinical and Applied Thrombosis/Hemostasis

Volumn 4, Issue 3, 1998, Pages 189-195

  Strekerud, Finn G ^a   Abildgaard, Ulrich ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Drug monitoring; Heparinoid; Low molecular weight heparins; Oral anticoagulation; Prothrombin time; Unfractioned heparin

Indexed keywords

DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; HEPARINOID; LOGIPARIN DINNOHEP; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; DRUG MONITORING; HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 0031841718     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969800400308     Document Type: Article

References (18)

1. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted treatment of deep venous thrombosis: a comparison of unfractioned and low molecular weight heparin. Eur J Pharmacol 1990:39:107.
2. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low molecular weight heparin in acute deep venous thrombosis. Haemostasis 1990;20(suppl 1):205.
3. Abildgaard U, Norrheim L, Larsen AE, et al. Monitoring therapy with LMW Heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay. Haemostasis 1990;20:193.
4. Nycomed Pharma. Nycoplastin, Nycotest PT, Thrombotest, product prescriptions. Majorstua, Oslo, Norway, 1990.
5. Diagnostica STAGO. Stago Prothrombin Complex Assay (SPA), product prescription. Franconville, France, 1993.
6. Eichinger S, Woltz M, Nieszpaur-Los M, et al. Effects of a low molecular weight heparin (Fragmin) and unfractioned heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost 1994;72:831.
7. Organon: Orgaran, product prescription. Organon, Oss, Netherlands, 1992.
8. Hull RD, Pineo GF. Therapeutic use of low molecular weight heparins. Haemostasis 1993;23(suppl 1):2.
9. Holmstrøm I, Berglund MC, Granquist S, et al. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992;67:49.
10. Loeliger EA. Therapeutic target values in oral anticoagulation-Justification of Dutch policy and a warning against the so called moderate - intensity regimens. Ann Hematol 1992;64:60.
11. Strekerud FG, Abildgaard U. aPTT in heparinized plasma; influence of reagent, acute-phase reaction, and interval between sampling and testing. Clin Appl Thromb Hemost 1996;2:250.
12. British Society for Hematology, British Committee for Standards in Hematology, Hemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43:177.
13. Alshameeri R, Mammen EF, Paisley C, Perry C. Validity of international normalized ratio in expressing prothrombin times in anticoagulated and nonanticoagulated patients. Clin Appl Thromb Hemost 1996;2(1):25.
14. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutical range. Chest 1992;102:312.
15. Loeliger EA, Poller L, Samama M, et al. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985;54:515.
16. Taberner DA, Poller L, Thomson JM, et al. The effect of the international sensitivity index (ISI) of thromboplastin on the precision of international normalized ratios (INR). J Clin Pathol 1989; 42:92.
17. Poller L, Taberner DA, Thomson JM, et al. Survey of prothrombin time in national external quality assessment scheme exercises (1980-87). J Clin Pathol 1988;41:361.
18. McKernan A, Thomson JM, Poller L. The reliability of international normalized ratio during short-term oral anticoagulant therapy. Clin Lab Hemost 1988;10:63.